Search results
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
The Woonsocket Call· 6 days agoImmunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully ...
...At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable...
Benzinga· 4 days agoResults from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated...
Binge-Eating Disorder May Linger for Years
Medscape· 3 days agoBinge-eating disorder (BED) often improves with time, but full remission can take many years and relapse is common, new research suggested. "The big...
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 7 days agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using...
Benzinga· 6 days agoStudy shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoThe results showed a 12-month overall survival (“OS”) rate of 69%, a median overall survival (“mOS”) of 17.5 months, and a 30% overall response rate (“ORR ...
Immunotherapy significantly increases the number of patients free from bowel cancer: Clinical trial
Medical Xpress· 5 days agoThe trial was a collaboration among UCL, UCLH, the Christie NHS Foundation Trust in...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 4 days agoBristol Myers Squibb & Co BMY announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12...
Docetaxel Tied to Less Taxane Neuropathy in Black Breast Cancer Patients
MedPage Today· 2 days agoGermline variations did not predict the risk of taxane-induced peripheral neuropathy (TIPN) in a...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 4 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...